Replimune Group (REPL)

• Market cap: $784M
• 1 day: -1.87%
• 5 days: -5.75%
• 1 month: 13.91%
• 3 months: 76.19%
• 6 months: 1.63%
• Year to date: -20.46%
• 1 year: -19.95%
• 5 years: -76.43%
• 10 years: -34.1%
• Sector: Healthcare
• Industry: Biotechnology

About: Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.

Employees: 479